Literature DB >> 3112021

[Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

M S Collins, R F Hector, R E Roby, A A Edwards, D K Ladehoff, J H Dorsey.   

Abstract

Three immunoglobulin preparations for intravenous infusion were compared in vivo to determine their relative protective capacity against several gram-negative and gram-positive pathogens. Polyglobin N is a conventional IgG concentrate. Psomaglobin N is identical in formulation to Polyglobin N but is prepared from the plasma of donors who have naturally high levels of antibody to lipopolysaccharide antigens of Pseudomonas aeruginosa. IgGMA is a conventional IgG concentrate containing 12% IgG and 16% IgA. In a murine model of burn wound sepsis the three IgG preparations were similarly protective against three or ten strains of P. aeruginosa. Psomaglobin N and Polyglobin N were significantly (p less than or equal to 0.015) more protective than IgGMA against six of ten and three of ten strains of P. aeruginosa, respectively. In a murine model of Streptococcus pneumoniae type 3 pneumonia, the three Ig preparations were similarly protective. IgGMA was significantly more protective (p less than or equal to 0.025) than Psomaglobin N and Polyglobin N against Salmonella typhimurium in murine peritonitis. However, the mean protective dose (PD50) of the two later preparations was less than or equal to 20 mg/kg body weight. In models of peritonitis both Psomaglobin N and Polyglobin N were more protective than IgGMA (p less than or equal to 0.004) against Haemophilus influenzae b, Klebsiella pneumoniae, Serratia marcescens 06:H3 and group B Streptococcus types 1b and 1c. Psomaglobin N and ciprofloxacin were employed to treat established polymicrobial murine burn wound sepsis resulting from contamination of the burn site with mixtures of P. aeruginosa and Staphylococcus aureus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112021     DOI: 10.1007/bf01644193

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

Review 1.  The gamma globulins. 3. The antibody deficiency syndromes.

Authors:  F S Rosen; C A Janeway
Journal:  N Engl J Med       Date:  1966-09-29       Impact factor: 91.245

2.  Undegraded human immunoglobulin for intravenous use.

Authors:  W Stephan
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

3.  Binding of protein A to some human gamma-globulins used intravenously.

Authors:  M Ceska
Journal:  Vox Sang       Date:  1981       Impact factor: 2.144

4.  Comparative in vivo activity between intravenous immune globulin prepared by reduction and alkylation or by low pH.

Authors:  M S Collins; J H Dorsey
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

5.  Evaluation of gamma globulin for prophylaxis against burn sepsis.

Authors:  H H Stone; C D Graber; J D Martin; L Kolb
Journal:  Surgery       Date:  1965-11       Impact factor: 3.982

6.  Burn wound infection.

Authors:  W F McManus; C W Goodwin; A D Mason; B A Pruitt
Journal:  J Trauma       Date:  1981-09

7.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  Exotoxin production by clinical isolates of pseudomonas aeruginosa.

Authors:  M Pollack; N S Taylor; L T Callahan
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

10.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

View more
  2 in total

Review 1.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 2.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.